Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 114

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 114
---
 method of distributing these
securities.

| 73 |

| Name of Selling Shareholder     |     | Number of Ordinary 
 Shares Owned Prior 
 to Offering (1)    |     | Maximum Number of        
 Ordinary Shares to       
 be Sold Pursuant to this 
 Prospectus               |                 |     | Number of          
 Ordinary           
 Shares Owned After 
 Offering (2)       |     | Percentage   
 of Ordinary  
 Shares Owned 
 after the    
 Offering (3) |
| C/M Capital Master Fund, LP (4) |     | --                 |     |                          | 341,352,000,000 |     | --                 |     | --           |

_____________

| (1) | In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially                             
 owned prior to the offering all of the shares that the Selling Shareholder may be required to purchase under the Purchase Agreement, because 
 the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction   
 of which are entirely outside of the Selling Shareholder’s control, including the registration statement that includes this prospectus       
 becoming and remaining effective. Furthermore, the Fixed Purchases, VWAP Purchase, or Additional VWAP Purchase, as applicable, of Depositary 
 Shares is subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreement. Also, the Purchase Agreement        
 prohibits us from issuing and selling any of our Depositary Shares to the Selling Shareholder to the extent such shares, when aggregated     
 with all other securities then beneficially owned by the Selling Shareholder, would cause the Selling Shareholder beneficial ownership       
 of our Ordinary Shares to exceed the Beneficial Ownership Limitation.                                                                        |

| (2) | Assumes that all Ordinary Shares being registered under the registration                                                                
 statement of which this prospectus forms a part are sold in this offering, and that none of the Selling Shareholders acquire additional 
 Ordinary Shares after the date of this prospectus and prior to completion of this offering.                                             |

| (3) | Applicable percentage ownership                                             
 is based on 25,617,408,922 Ordinary Shares outstanding as of April 1, 2025. |

| (4) | The business address of C/M Capital Master Fund, LP is 1111 Brickell Avenue, Suite 2920, Miami, Florida                                  
 33131. As of the date of the Purchase Agreement, C/M Capital Master Fund, LP did not